Lu Daopei Hematology Hospital
Hematology oncology treatment in China typically costs from $18,800 to $146,900. Final expenses depend on the cancer stage, the use of domestic versus imported medications, and the specific cell therapy protocols required. Patients often find 50–85% savings compared to the United States for advanced blood cancer treatments.
Typical Hematology Oncology Costs in China
Major hematology centers are concentrated in Beijing, Shanghai, and Guangzhou. Costs in these Tier-1 cities are generally higher than in regional facilities due to advanced technology. You should consult with a specialist to get accurate pricing for your specific medical case.
| China | Turkey | Austria | |
| Plasmapheresis | from $2,200 | from $1,200 | from $2,000 |
| Lymphoma chemotherapy | from $18,500 | from $3,000 | from $8,000 |
| Chemotherapy | from $3,800 | from $2,430 | from $2,500 |
| CAR T-cell therapy | from $165,000 | from $150,000 | from $350,000 |
| Bone marrow transplantation | from $55,000 | from $36,000 | from $140,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Hematology Oncology treatment upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Hematology Oncology treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Hematology Oncology treatment journey.
Dr. Li Ping, M.D., Ph.D., is Chief Physician and Professor in the Department of Hematology at Shanghai Tongji Hospital, Tongji University School of Medicine. She supervises doctoral and master's students and is an expert in hematologic malignancies.
She earned a Doctor of Medical Science from Nagoya University and completed postdoctoral research. She specializes in diagnosing and treating blood cancers. Her focus includes lymphoid malignancies—leukemias, lymphomas, and multiple myeloma. She treats patients with chemotherapy, hematopoietic stem cell transplantation, targeted therapy, and immunotherapy.
She is a pioneer in China in full-cycle CAR-T therapy for relapsed or refractory blood cancers. She leads and participates in national and international clinical trials. She serves on committees of professional societies, including the China Anti-Cancer Association. She also publishes and trains hematologists.
Professor Liang Xiaoxiao is the Department Director and Chief Physician in Neurorehabilitation. She holds a master’s degree in neurology. She is skilled in neuromodulation for disorders of consciousness, cognition, and movement. Her focus includes cases from cerebrovascular disease, Parkinson’s disease, and related conditions. She also performs ultrasound-guided botulinum toxin injections for blepharospasm, hemifacial spasm, limb spasticity, sialorrhea, and neuralgia.
Accreditations and roles: Member of the Neurorehabilitation, Cognitive Disorder Rehabilitation, and Craniocerebral Trauma Rehabilitation Committees of the Chinese Association of Rehabilitation Medicine. Standing Member of the Cognitive Disorder Rehabilitation Committee of the Fujian Association of Rehabilitation Medicine. Vice Chair of the Dementia and Cognitive Disorder Committee of the Xiamen Preventive Medicine Association. Vice President of the Parkinson’s Disease and Movement Disorders Committee of the Xiamen Medical Doctor Association. Standing Member of the Neuromodulation Committee of the Xiamen Medical Doctor Association. Recipient of the Most Beautiful Physician of Xiamen City (2024).
Dr. Liu Shi Xin is the Vice Chairman of the Radiation Oncology Branch of the Chinese Medical Association. He serves as the Discipline Leader of the Oncology Center at Xiamen Humanity Hospital. Dr. Liu specializes in precision radiotherapy for thoracic and abdominal cancers. He is a recipient of the State Council Special Government Allowance for his medical contributions.
Written by Anna Leonova
Written by Anna Leonova
Written by Halina Shubala
China integrates Traditional Chinese Medicine (TCM) into oncology through a dual-track system combining Western surgery or chemotherapy with herbal restorative care. This multidisciplinary model aims to eliminate tumors while rebuilding the immune system. Between 64% and 80% of Chinese cancer patients use TCM during treatment.
Bookimed Expert Insight: While many expect TCM to be an alternative, China's elite Class A Level III hospitals, like Yanda International, treat it as a mandatory clinical standard. Data shows these top-tier centers use TCM to stabilize blood counts faster after intensive procedures. Patients should prioritize JCI-accredited facilities to ensure herbal potency is strictly regulated alongside Western diagnostics.
Patient Consensus: Patients note that TCM is culturally essential in China and helps make side effects from treatments like rituximab feel much milder. However, they emphasize the need to monitor liver function closely when using herbal formulas alongside active chemotherapy.
Doctors in China assess hematology-oncology treatment using blood tests, medical imaging, and bone marrow biopsies. These tests track tumor shrinkage and blood cell normalization. Specialized centers like Lu Daopei Hematology Hospital use high-volume data to monitor response. They focus on cellular recovery and genetic markers.
Bookimed Expert Insight: Quality signals in China often correlate with hospital scale and specialized focus. Lu Daopei Hematology Hospital manages 200,000 patients annually across 30 departments. This massive volume allows doctors like Dr. Lu Peihua to recognize subtle response patterns faster. Large-scale facilities often provide quicker test turnarounds than smaller general clinics.
Patient Consensus: Patients note that physical signs like improved energy and reduced bruising often appear before laboratory shifts. They emphasize that regular blood draws are the primary way doctors track early progress between major scans.
International patients typically require an S1 or S2 Private Affairs visa for oncology treatment in China. The S2 visa covers stays under 180 days for surgeries. The S1 visa is for longer treatments exceeding 180 days. Both versions require an official invitation from a government-accredited hospital.
Bookimed Expert Insight: High-volume centers like Yanda International Hospital or Xiamen Humanity Hospital handle over 1,000,000 patients annually. These Class A Level 3 facilities have dedicated departments to streamline visa invitations. This institutional support is vital because they can help convert initial entry visas into medical residency permits once treatment begins.
Patient Consensus: Patients note that hospital-sponsored invitations are more reliable than standard tourist visas for long oncology stays. They emphasize that while some enter on tourist visas, upgrading internally is necessary to avoid deportation during intensive treatment cycles.
English-speaking support in Chinese hematology oncology centers varies significantly by facility type. Top-tier institutions like Fuda Cancer Hospital and Yanda International Hospital hold JCI accreditation. These centers frequently provide dedicated international departments. Staff in these wings often speak English to assist the 30,000+ international patients treated annually.
Bookimed Expert Insight: High-volume centers like Yanda International Hospital manage over 2,500,000 patients annually. Our data shows these `Class A level III` clinics are the most likely to have formal translation infrastructure. If you choose a specialized center like Lu Daopei, we recommend confirming support in writing before your stay. This ensures complex hematology protocols are clearly understood by all parties.
Patient Consensus: Patients note that while top doctors may speak basic English, daily care often requires translation apps like Pleco. It is helpful to prepare Mandarin terms for specific conditions like neutropenia or chemotherapy side effects before arrival.
Patients should plan to stay in China for 3 to 10 weeks for hematology-oncology care. Initial evaluations typically take 3 to 7 days. Advanced treatments like CAR-T cell therapy require 4 to 10 weeks for cell engineering and post-infusion monitoring.
Bookimed Expert Insight: High-volume centers like Yanda International Hospital and Xiamen Humanity Hospital manage over 1,000,000 patients annually. This massive scale allows JCI-accredited facilities to offer thousands of modern technologies and drug trials that may not be available elsewhere. Patients should verify their specific treatment regimen early, as initial plans can change once on-site diagnostics are completed by specialists like Dr. Lu Peihua.
Patient Consensus: Patients emphasize budgeting an extra 2 weeks for potential appointment backlogs and recovery delays. It is highly recommended to hire a Mandarin-speaking medical translator and arrange long-term apartment housing near the hospital for comfort.
Family members can generally stay with you in Chinese hematology-oncology facilities. Policies vary by hospital type and room category. International-standard centers like Fuda Cancer Hospital offer more flexibility. Specialized units have stricter rules to protect immuno-compromised patients. General visiting hours usually run from 8 a.m. to 8 p.m.
Bookimed Expert Insight: Data from high-volume centers like Yanda International Hospital, which serves 2,500,000 patients annually, shows a preference for integrated care. Facilities with JCI accreditation typically offer better infrastructure for families. If family presence is your priority, look for clinics with over 1,000 beds. These larger campuses often include on-site hotel apartments or specialized family lounges.
Patient Consensus: Patients note that while standard rooms have strict night-time exits, paying for the family bed add-on makes a huge difference. Many families find it most practical to rent nearby apartments for long-term chemotherapy sessions to avoid hospital exhaustion.
Patients can obtain a remote second opinion for hematology oncology before traveling to China. Leading facilities like Fuda Cancer Hospital and Lu Daopei Hematology Hospital offer these services. Consultations typically use secure video platforms or written reports to validate diagnoses and treatment strategies before international travel.
Bookimed Expert Insight: Clinics with high patient volumes, such as Yanda International Hospital with 2,500,000 annual visits, often employ internal translation teams. These facilities seamlessly bridge language gaps for international cases. Choosing a JCI-accredited center like Fuda Cancer Hospital ensures that your remote consultation follows globally recognized safety and quality standards.
Patient Consensus: Patients note that sending pathology slides ahead via courier is vital for accurate remote analysis. Many find that using English-speaking coordinators helps navigate language barriers when uploading records to Chinese oncology platforms.
Chinese haematology and oncology protocols follow guidelines from the CSCO (Chinese Society of Clinical Oncology) and CSH (Chinese Society of Hematology). These domestic standards adapt global frameworks like NCCN to local drug availability. Top clinics also use standards from the NHC (National Health Commission).
Bookimed Expert Insight: China's top tier hospitals, like the Class A level III Yanda International Hospital, often combine these domestic standards with international protocols. Specialists like Prof. Liu Shi Xin at Xiamen Humanity Hospital hold leadership roles in both the CMA and CSCO. This dual expertise helps patients receive treatments that meet local regulatory requirements and global precision radiotherapy standards.
Patient Consensus: Patients find the transition to Chinese care smooth when clinics provide clear regimens. They appreciate the detailed preliminary consultations and the integration of specialised therapies with traditional support.
Western-approved CAR-T therapies and targeted drugs are available in China for haematology oncology. Treatments like Yescarta and Carvykti are accessible alongside domestically developed options. These therapies are regulated by the NMPA (National Medical Products Administration). They are administered in major tertiary centres and specialised haematology hospitals.
Bookimed Expert Insight: Major centres in Beijing and Guangzhou offer these therapies. However, the Hainan Boao Lecheng pilot zone is an important detail. This zone allows doctors to legally import Western-approved drugs. They can use them before they receive full mainland clearance. This zone provides a legal way to access specific targeted drugs earlier.
Patient Consensus: Patients note that access depends heavily on the hospital and trial eligibility. They suggest confirming the drug brand and aftercare plan before travelling. This helps to avoid any surprises during follow-up.
Precision medicine and Next-Generation Sequencing (NGS) are well established in China. These markets grow at 21% annually. Centres in major cities use genomic profiling to guide CAR T-cell therapy and immunotherapy. JCI-accredited facilities like Fuda Cancer Hospital provide molecular diagnostics for complex cases.
Bookimed Expert Insight: China's top oncology centres often bypass traditional chemotherapy for late-stage cases. Fuda Cancer Hospital combines molecular insights with over 10 types of minimally invasive therapies. These include NanoKnife and cryosurgery. This approach targets tumours while reducing the side effects common with standard chemo.
Patient Consensus: Patients find that precision services are most reliable in hubs like Beijing or Guangzhou. They note it is vital to check if a hospital interprets NGS results in-house. This helps patients avoid treatment delays in China.
Remote consultations for haematology oncology in China are widely accessible. They cost from $300 to $400. These online sessions verify eligibility for treatments like CAR T-cell therapy before travel. JCI-accredited facilities in Beijing and Guangzhou routinely provide these reviews for international patients.
Bookimed Expert Insight: Clinics with high patient volumes often have more streamlined digital infrastructure. Xiamen Humanity Hospital, for example, sees 1,000,000 annual patients. Larger facilities typically offer faster upload speeds for medical imaging files. They also offer quicker scheduling for urgent video conferences. This efficiency is vital when timing determines the success of blood disorder treatments.
Patient Consensus: Patients find that remote reviews provide clear direction for their care. These sessions clarify the treatment regimen before departure. Discussing complex cases with specialists in Beijing or Guangzhou helps families feel prepared for the journey.
Traditional Chinese Medicine (TCM) is integrated directly and concurrently into Western haematology oncology treatments in China. This federally mandated strategy is known as Integrated Traditional Chinese and Western Medicine (ITCWM). It allows top-tier hospitals to provide both paradigms under one roof. These centres use both methods to manage blood cancers and treatment-induced side effects.
Bookimed Expert Insight: Many equate TCM with folk medicine. However, China's Class A Level III clinics like Yanda International Hospital treat it as a clinical discipline. These hospitals use intravenous TCM drips administered in the same ward as standard chemotherapy. This internal standardisation helps herbal interventions not interfere with Western drug efficacy or stem cell transplant monitoring.
Patient Consensus: Patients find TCM is used mostly for recovery and managing nausea rather than as a primary cure. Many note that TCM specialists work in the same health ecosystem. This allows for easier coordination during intensive blood cancer treatments in China.
New oncology drugs entering the Chinese market currently face a median time lag of 2.7 to 3.5 years. This delay occurs after the first global launch. Regulatory pathways like Priority Review and Breakthrough Therapy Designation now streamline the approval process. The National Medical Products Administration (NMPA) handles these approvals.
Bookimed Expert Insight: While drug lags exist, Chinese hubs like Xiamen Humanity Hospital often lead in clinical trials. They conduct Phase 1–4 trials for global assets. This gives patients access to the latest therapies years before they hit the general market. This high-volume environment allows clinicians to master emerging treatments like Boron Neutron Capture Therapy. They often do this earlier than most Western centres.
Patient Consensus: Patients note that initial treatment plans may change after arrival once local diagnostics are complete. They value precision technologies like the Da Vinci robot and specialised radiotherapy. These are available at major facilities in Beijing and Guangzhou.